XML 85 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Sale of Equity Interests in Theravance Respiratory Company, LLC and Discontinued Operations (Details)
12 Months Ended
Jul. 20, 2022
USD ($)
shares
Feb. 21, 2020
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Theravance Respiratory Company, LLC          
Future contingent milestone and royalty assets     $ 194,200,000    
Royalty Pharma | Disposed of by Sale | TRC          
Theravance Respiratory Company, LLC          
Net gain from sale of equity interests in TRC, LLC $ 1,141,100,000   1,141,084,000    
Consideration received 1,301,600,000        
Proceeds from the sale of equity interest in TRC, LLC 1,107,400,000        
Equity method investments 136,700,000        
Future contingent milestone and royalty assets 194,200,000        
Transaction costs 23,800,000        
Income from investments in TRC, LLC     53,237,000 $ 103,987,000 $ 68,438,000
Investment Amount $ 136,700,000        
Royalty Pharma | Disposed of by Sale | TRC | Measurement Input, Discount Rate [Member]          
Theravance Respiratory Company, LLC          
Equity method investment, contingent consideration 0.0783        
Royalty Pharma | Purchase Agreement to Sell Units in Theravance Respiratory Company, LLC          
Theravance Respiratory Company, LLC          
Percentage of Right to Receive Royalty Transferring 85        
Proceeds from sale of units. $ 1,100,000,000        
Consideration Receivable at closing $ 250,000,000.0        
Royalty Pharma | Class B Units | Purchase Agreement to Sell Units in Theravance Respiratory Company, LLC          
Theravance Respiratory Company, LLC          
Units issued | shares 2,125        
Royalty Pharma | Class C Units | Purchase Agreement to Sell Units in Theravance Respiratory Company, LLC          
Theravance Respiratory Company, LLC          
Units issued | shares 6,375        
TRC          
Theravance Respiratory Company, LLC          
Percentage of equity interest       85.00%  
Percentage of economic interest   85.00%   85.00%  
Equity method investments     0 $ 67,500,000  
Income from investments in TRC, LLC     53,200,000 104,000,000.0 $ 68,400,000
Due form TRC     0 43,500,000  
Investment Amount     $ 0 $ 67,500,000  
Number of fiscal quarters       4  
Theravance          
Theravance Respiratory Company, LLC          
Consideration Receivable at closing $ 1,326,600,000